Central nervous system complications in SARS-CoV-2-infected patients
Authors:
Open Access
- 13 August 2023
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (10) , 4617-4631
Abstract
Objective: To investigate the clinical manifestations, treatment and prognosis of COVID-19-associated central nervous system (CNS) complications. Methods: In this single-centre observation study, we recruited patients with COVID-19-associated CNS complications at the neurology inpatient department of the Eighth Affiliated Hospital, Sun Yat-Sen University (Futian, Shenzhen) from Dec 2022 to Feb 2023. Patients were analysed for demographics, clinical manifestations, cerebrospinal fluid properties, electroencephalographic features, neuroimaging characteristics, and treatment outcome. All patients were followed-up at 1 and 2 months after discharge until Apr 2023. Results: Of the 12 patients with COVID-19-associated CNS complications, the CNS symptoms occur between 0 days and 4 weeks after SARS-CoV-2 infection. The most common CNS symptoms were memory deficits (4/12, 33%), Unresponsiveness (4/12, 33%), mental and behavioural disorders (4/12, 33%). Seven of 12 cases can be categorized as probable SARS-CoV-2 encephalitis, and 5 cases can be described as brainstem encephalitis, acute disseminated encephalomyelitis, optic neuritis, multiple sclerosis or tremor probably associated with SARS-CoV-2 infection. Six patients received antiviral therapy, and 11 patients received glucocorticoid therapy, of which 3 patients received human immunoglobulin synchronously. Nine patients recovered well, two patients had residual neurological dysfunction, and one patient passed away from complications associated with tumor. Conclusion: In this observational study, we found that the inflammatory or immune-related complications were relatively common manifestations of COVID-19-associated CNS complications, including different phenotypes of encephalitis and CNS inflammatory demyelinating diseases. Most patients recovered well, but a few patients had significant neurological dysfunctions remaining.Keywords
Funding Information
- Guangzhou Science and Technology Research Project, China (2018B030337001, 2022A1515110993)
- Basic Research of Shenzhen Science and Technology Project, China (JCYJ20210324115008022, JCYJ20220530144211024)
- Health Public Welfare Scientific Research Projects of Futian, China (FTWS2021069, FTWS2022010)
This publication has 71 references indexed in Scilit:
- Pathological mechanisms in progressive multiple sclerosisThe Lancet Neurology, 2015
- Focal disturbances in the blood–brain barrier are associated with formation of neuroinflammatory lesionsNeurobiology of Disease, 2015
- Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis ConsortiumClinical Infectious Diseases, 2013
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaNew England Journal of Medicine, 2012
- Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective studyThe Lancet Infectious Diseases, 2010
- The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2008
- The Immunopathology of Multiple Sclerosis: An OverviewBrain Pathology, 2007
- Idiopathic hyposmia as a preclinical sign of Parkinson's diseaseAnnals of Neurology, 2004
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003The Lancet, 2003